Quick Answer
TELA Bio, Inc. reported Gross Profit of $54.34 million for the year ending 2025.
- TELA Bio, Inc. showed an increase of +16.9% in Gross Profit from 2024 to 2025.
- This data is from TELA Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $1.37 million | Q1 2019: $1.80 million | Q2 2019: $1.91 million | Q3 2019: $2.60 million | Q1 2020: $2.20 million | Q2 2020: $2.09 million | Q3 2020: $3.29 million | Q1 2021: $3.47 million | Q2 2021: $5.09 million | Q3 2021: $4.60 million | Q1 2022: $5.00 million | Q2 2022: $6.55 million | Q3 2022: $7.32 million | Q1 2023: $7.90 million | Q2 2023: $10.20 million | Q3 2023: $10.39 million | Q1 2024: $11.34 million | Q2 2024: $11.07 million | Q3 2024: $12.86 million | Q1 2025: $12.51 million | Q2 2025: $14.11 million | Q3 2025: $13.97 million.
- Over the full 9 years of available data (2017 to 2025), TELA Bio, Inc.'s Gross Profit has grown by 2,046.2%.
- Historical annual values: Fiscal year 2025: $54.34 million | Fiscal year 2024: $46.49 million | Fiscal year 2023: $40.11 million | Fiscal year 2022: $27.04 million | Fiscal year 2021: $18.81 million | Fiscal year 2020: $11.23 million | Fiscal year 2019: $9.27 million | Fiscal year 2018: $2.94 million | Fiscal year 2017: $2.53 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: